KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Receivables: 2010-2023

Historic Receivables for Nektar Therapeutics (NKTR) over the last 14 years, with Dec 2023 value amounting to $1.7 million.

  • Nektar Therapeutics' Receivables was N/A to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2023, which is 74.48% down from last year.
  • Per Nektar Therapeutics' latest filing, its Receivables stood at $1.7 million for FY2023, which was down 74.48% from $6.7 million recorded in FY2022.
  • Nektar Therapeutics' 5-year Receivables high stood at $44.0 million for FY2020, and its period low was $1.7 million during FY2023.
  • Over the past 3 years, Nektar Therapeutics' median Receivables value was $6.7 million (recorded in 2022), while the average stood at $10.8 million.
  • Per our database at Business Quant, Nektar Therapeutics' Receivables rose by 1.59% in 2020 and then tumbled by 74.48% in 2023.
  • Over the past 5 years, Nektar Therapeutics' Receivables (Yearly) stood at $43.3 million in 2019, then grew by 1.59% to $44.0 million in 2020, then slumped by 45.69% to $23.9 million in 2021, then tumbled by 72.04% to $6.7 million in 2022, then plummeted by 74.48% to $1.7 million in 2023.